Tolerance and immune suppression in the tumor microenvironment

Cellular Immunology

Volumn 299, Issue , 2016, Pages 23-29

  Ostrand Rosenberg, Suzanne ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

Immune suppression; MDSC; Myeloid derived suppressor cells; Tolerance; Tumor immunology

Indexed keywords

CELL MARKER; IMMUNOMODULATING AGENT;

ARTICLE; BONE MARROW CELL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL FUNCTION; CELL INTERACTION; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; MYELOID DERIVED SUPPRESSOR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; BOVINE; HISTORY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; NEOPLASM; TUMOR ESCAPE;

ANIMALS; CATTLE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MYELOID CELLS; NEOPLASMS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84945908483     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2015.09.011     Document Type: Article

References (113)

1. [1] Owen, R.D., Immunogenetic consequences of vascular anastomoses between bovine twins. Science 102 (1945), 400–401.
2. [2] Ehrlich, P., Über den jetzigen stand der karzinomforschung. Ned. Tijdschr. Geneeskd. 5 (1909), 273–290.
3. [3] Coley, W., The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105 (1893), 487–511.
4. [4] Thomas, L., Discussion of cellular and humoral aspects of the hypersensitivity states. Lawrence, H., (eds.) Cellular and Humoral Aspects of Hypersensitivity, 1959, Hoeber-Harper, New York, 529–532.
5. [5] Burnet, M., Immunological factors in the process of carcinogenesis. Br. Med. Bull. 20 (1964), 154–158.
6. [6] Burnet, F.M., Immunological aspects of malignant disease. Lancet 1 (1967), 1171–1174.
7. [7] Stutman, O., Immunodepression and malignancy. Adv. Cancer Res. 22 (1975), 261–422.
8. [8] Stutman, O., Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J. Natl Cancer Inst. 62 (1979), 353–358.
9. [9] Maleckar, J.R., Sherman, L.A., The composition of the T cell receptor repertoire in nude mice. J. Immunol. 138 (1987), 3873–3876.
10. [10] Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J., Schreiber, R.D., IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001), 1107–1111.
11. [11] Burnet, F.M., Fenner, F., The Production of Antibodies. 1949, McMillan, London.
12. [12] Billingham, R.E., Brent, L., Medawar, P.B., Actively acquired tolerance of foreign cells. Nature 172 (1953), 603–606.
13. [13] Fenton, R.G., Longo, D.L., Genetic instability and tumor cell variation: implications for immunotherapy. J. Natl Cancer Inst. 87 (1995), 241–243.
14. [14] Strober, S., Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation: exploring obscure relationships. Annu. Rev. Immunol. 2 (1984), 219–237.
15. [15] Young, M.R., Young, M.E., Wright, M.A., Myelopoiesis-associated suppressor-cell activity in mice with Lewis lung carcinoma tumors: interferon-gamma plus tumor necrosis factor-alpha synergistically reduce suppressor cell activity. Int. J. Cancer 46 (1990), 245–250.
16. [16] Garrity, T., Pandit, R., Wright, M.A., Benefield, J., Keni, S., Young, M.R., Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. Int. J. Cancer 73 (1997), 663–669.
17. [17] Young, M.R., Wright, M.A., Lozano, Y., Matthews, J.P., Benefield, J., Prechel, M.M., Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int. J. Cancer 67 (1996), 333–338.
18. [18] Young, M.R., Wright, M.A., Lozano, Y., Prechel, M.M., Benefield, J., Leonetti, J.P., Collins, S.L., Petruzzelli, G.J., Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int. J. Cancer 74 (1997), 69–74.
19. [19] Almand, B., Clark, J.I., Nikitina, E., van Beynen, J., English, N.R., Knight, S.C., Carbone, D.P., Gabrilovich, D.I., Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166 (2001), 678–689.
20. [20] Bronte, V., Wang, M., Overwijk, W.W., Surman, D.R., Pericle, F., Rosenberg, S.A., Restifo, N.P., Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J. Immunol. 161 (1998), 5313–5320.
21. [21] Gabrilovich, D.I., Velders, M.P., Sotomayor, E.M., Kast, W.M., Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol. 166 (2001), 5398–5406.
22. [22] Schmielau, J., Finn, O.J., Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 61 (2001), 4756–4760.
23. [23] Gabrilovich, D.I., Bronte, V., Chen, S.H., Colombo, M.P., Ochoa, A., Ostrand-Rosenberg, S., Schreiber, H., The terminology issue for myeloid-derived suppressor cells. Cancer Res., 67, 2007, 425 (author reply 426).
24. [24] Gabrilovich, D.I., Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9 (2009), 162–174.
25. [25] Voisin, M.B., Buzoni-Gatel, D., Bout, D., Velge-Roussel, F., Both expansion of regulatory GR1+ CD11b+ myeloid cells and anergy of T lymphocytes participate in hyporesponsiveness of the lung-associated immune system during acute toxoplasmosis. Infect. Immun. 72 (2004), 5487–5492.
26. [26] Mencacci, A., Montagnoli, C., Bacci, A., Cenci, E., Pitzurra, L., Spreca, A., Kopf, M., Sharpe, A.H., Romani, L., CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J. Immunol. 169 (2002), 3180–3190.
27. [27] Sunderkotter, C., Nikolic, T., Dillon, M.J., Van Rooijen, N., Stehling, M., Drevets, D.A., Leenen, P.J., Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J. Immunol. 172 (2004), 4410–4417.
28. [28] Garg, A., Spector, S.A., HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. J. Infect. Dis. 209 (2014), 441–451.
29. [29] Heim, C.E., Vidlak, D., Scherr, T.D., Kozel, J.A., Holzapfel, M., Muirhead, D.E., Kielian, T., Myeloid-derived suppressor cells contribute to Staphylococcus aureus orthopedic biofilm infection. J. Immunol. 192 (2014), 3778–3792.
30. [30] Delano, M.J., Scumpia, P.O., Weinstein, J.S., Coco, D., Nagaraj, S., Kelly-Scumpia, K.M., O'Malley, K.A., Wynn, J.L., Antonenko, S., Al-Quran, S.Z., Swan, R., Chung, C.S., Atkinson, M.A., Ramphal, R., Gabrilovich, D.I., Reeves, W.H., Ayala, A., Phillips, J., Laface, D., Heyworth, P.G., Clare-Salzler, M., Moldawer, L.L., MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 204 (2007), 1463–1474.
31. [31] Sander, L.E., Sackett, S.D., Dierssen, U., Beraza, N., Linke, R.P., Muller, M., Blander, J.M., Tacke, F., Trautwein, C., Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J. Exp. Med. 207 (2010), 1453–1464.
32. [32] Makarenkova, V.P., Bansal, V., Matta, B.M., Perez, L.A., Ochoa, J.B., CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 176 (2006), 2085–2094.
33. [33] Mundy-Bosse, B.L., Thornton, L.M., Yang, H.C., Andersen, B.L., Carson, W.E., Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cell. Immunol. 270 (2011), 80–87.
34. [34] Grizzle, W.E., Xu, X., Zhang, S., Stockard, C.R., Liu, C., Yu, S., Wang, J., Mountz, J.D., Zhang, H.G., Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech. Ageing Dev. 128 (2007), 672–680.
35. [35] Verschoor, C.P., Johnstone, J., Millar, J., Dorrington, M.G., Habibagahi, M., Lelic, A., Loeb, M., Bramson, J.L., Bowdish, D.M., Blood CD33(+)HLA-DR(−) myeloid-derived suppressor cells are increased with age and a history of cancer. J. Leukoc. Biol. 93 (2013), 633–637.
36. [36] Gallina, G., Dolcetti, L., Serafini, P., De Santo, C., Marigo, I., Colombo, M.P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., Bicciato, S., Bronte, V., Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116 (2006), 2777–2790.
37. [37] Huang, B., Pan, P.Y., Li, Q., Sato, A.I., Levy, D.E., Bromberg, J., Divino, C.M., Chen, S.H., Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66 (2006), 1123–1131.
38. [38] Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., Van Ginderachter, J.A., Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111 (2008), 4233–4244.
39. [39] Sinha, P., Okoro, C., Foell, D., Freeze, H.H., Ostrand-Rosenberg, S., Srikrishna, G., Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181 (2008), 4666–4675.
40. [40] Youn, J.I., Nagaraj, S., Collazo, M., Gabrilovich, D.I., Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181 (2008), 5791–5802.
41. [41] Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., Bronte, V., Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22 (2010), 238–244.
42. [42] Parker, K., Sinha, P., Horn, L.A., Clements, V.K., Yang, H.C., Li, J., Tracey, K.J., Ostrand-Rosenberg, S., High mobility group box protein 1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res., 2014.
43. [43] Sinha, P., Clements, V.K., Bunt, S.K., Albelda, S.M., Ostrand-Rosenberg, S., Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179 (2007), 977–983.
44. [44] Beury, D.W., Parker, K.H., Nyandjo, M., Sinha, P., Carter, K.A., Ostrand-Rosenberg, S., Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J. Leukoc. Biol. 96 (2014), 1109–1118.
45. [45] Ostrand-Rosenberg, S., Sinha, P., Beury, D.W., Clements, V.K., Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin. Cancer Biol., 2012.
46. [46] Li, H., Han, Y., Guo, Q., Zhang, M., Cao, X., Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 182 (2009), 240–249.
47. [47] Liu, C., Yu, S., Kappes, J., Wang, J., Grizzle, W.E., Zinn, K.R., Zhang, H.G., Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109 (2007), 4336–4342.
48. [48] Suzuki, E., Kapoor, V., Jassar, A.S., Kaiser, L.R., Albelda, S.M., Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11 (2005), 6713–6721.
49. [49] Ostrand-Rosenberg, S., Myeloid-derived suppressor cells. Ratcliffe, M., (eds.) Encyclopedia of Immunobiology, 2016, Elsevier.
50. [50] Yang, L., DeBusk, L.M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L.M., Carbone, D.P., Lin, P.C., Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6 (2004), 409–421.
51. [51] Yang, L., Huang, J., Ren, X., Gorska, A.E., Chytil, A., Aakre, M., Carbone, D.P., Matrisian, L.M., Richmond, A., Lin, P.C., Moses, H.L., Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13 (2008), 23–35.
52. [52] Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H., Yu, H., Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 118 (2008), 3367–3377.
53. [53] Boelte, K.C., Gordy, L.E., Joyce, S., Thompson, M.A., Yang, L., Lin, P.C., Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1. PLoS One, 6, 2011, e18534.
54. [54] Toh, B., Wang, X., Keeble, J., Sim, W.J., Khoo, K., Wong, W.C., Kato, M., Prevost-Blondel, A., Thiery, J.P., Abastado, J.P., Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol., 9, 2011, e1001162.
55. [55] Ezernitchi, A.V., Vaknin, I., Cohen-Daniel, L., Levy, O., Manaster, E., Halabi, A., Pikarsky, E., Shapira, L., Baniyash, M., TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J. Immunol. 177 (2006), 4763–4772.
56. [56] Rodriguez, P.C., Quiceno, D.G., Zabaleta, J., Ortiz, B., Zea, A.H., Piazuelo, M.B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E.M., Antonia, S., Ochoa, J.B., Ochoa, A.C., Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64 (2004), 5839–5849.
57. [57] Srivastava, M.K., Sinha, P., Clements, V.K., Rodriguez, P., Ostrand-Rosenberg, S., Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70 (2010), 68–77.
58. [58] Bronte, V., Zanovello, P., Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5 (2005), 641–654.
59. [59] Corzo, C.A., Cotter, M.J., Cheng, P., Cheng, F., Kusmartsev, S., Sotomayor, E., Padhya, T., McCaffrey, T.V., McCaffrey, J.C., Gabrilovich, D.I., Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 182 (2009), 5693–5701.
60. [60] Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., Gabrilovich, D., Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172 (2004), 464–474.
61. [61] Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber, D.L., Schneck, J., Gabrilovich, D.I., Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13 (2007), 828–835.
62. [62] Lu, T., Ramakrishnan, R., Altiok, S., Youn, J.I., Cheng, P., Celis, E., Pisarev, V., Sherman, S., Sporn, M.B., Gabrilovich, D., Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J. Clin. Invest. 121 (2011), 4015–4029.
63. [63] Burke, M., Choksawangkarn, W., Edwards, N., Ostrand-Rosenberg, S., Fenselau, C., Exosomes from myeloid-derived suppressor cells carry biologically active proteins. J. Proteome Res. 13 (2014), 836–843.
64. [64] Burke, M.C., Oei, M.S., Edwards, N.J., Ostrand-Rosenberg, S., Fenselau, C., Ubiquitinated proteins in exosomes secreted by myeloid-derived suppressor cells. J. Proteome Res. 13 (2014), 5965–5972.
65. [65] Klemm, F., Joyce, J.A., Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 25 (2015), 198–213.
66. [66] Murray, P.J., Allen, J.E., Biswas, S.K., Fisher, E.A., Gilroy, D.W., Goerdt, S., Gordon, S., Hamilton, J.A., Ivashkiv, L.B., Lawrence, T., Locati, M., Mantovani, A., Martinez, F.O., Mege, J.L., Mosser, D.M., Natoli, G., Saeij, J.P., Schultze, J.L., Shirey, K.A., Sica, A., Suttles, J., Udalova, I., van Ginderachter, J.A., Vogel, S.N., Wynn, T.A., Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41 (2014), 14–20.
67. [67] Bunt, S.K., Clements, V.K., Hanson, E.M., Sinha, P., Ostrand-Rosenberg, S., Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J. Leukoc. Biol. 85 (2009), 996–1004.
68. [68] Serafini, P., Mgebroff, S., Noonan, K., Borrello, I., Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68 (2008), 5439–5449.
69. [69] Mace, T.A., Ameen, Z., Collins, A., Wojcik, S., Mair, M., Young, G.S., Fuchs, J.R., Eubank, T.D., Frankel, W.L., Bekaii-Saab, T., Bloomston, M., Lesinski, G.B., Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res. 73 (2013), 3007–3018.
70. [70] Bodogai, M., Moritoh, K., Lee-Chang, C., Hollander, C.M., Sherman-Baust, C.A., Wersto, R.P., Araki, Y., Miyoshi, I., Yang, L., Trinchieri, G., Biragyn, A., Immunosuppressive and prometastatic functions of myeloid-derived suppressive cells rely upon education from tumor-associated B cells. Cancer Res. 75 (2015), 3456–3465.
71. [71] Terabe, M., Matsui, S., Park, J.M., Mamura, M., Noben-Trauth, N., Donaldson, D.D., Chen, W., Wahl, S.M., Ledbetter, S., Pratt, B., Letterio, J.J., Paul, W.E., Berzofsky, J.A., Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198 (2003), 1741–1752.
72. [72] Saleem, S.J., Martin, R.K., Morales, J.K., Sturgill, J.L., Gibb, D.R., Graham, L., Bear, H.D., Manjili, M.H., Ryan, J.J., Conrad, D.H., Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity. J. Immunol. 189 (2012), 511–515.
73. [73] Danelli, L., Frossi, B., Gri, G., Mion, F., Guarnotta, C., Bongiovanni, L., Tripodo, C., Mariuzzi, L., Marzinotto, S., Rigoni, A., Blank, U., Colombo, M.P., Pucillo, C.E., Mast cells boost myeloid-derived suppressor cell activity and contribute to the development of tumor-favoring microenvironment. Cancer Immunol. Res. 3 (2015), 85–95.
74. [74] Ostrand-Rosenberg, S., Sinha, P., Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182 (2009), 4499–4506.
75. [75] Gabrilovich, D.I., Chen, H.L., Girgis, K.R., Cunningham, H.T., Meny, G.M., Nadaf, S., Kavanaugh, D., Carbone, D.P., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2 (1996), 1096–1103.
76. [76] Young, M.R., Kolesiak, K., Wright, M.A., Gabrilovich, D.I., Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor. Clin. Exp. Metastasis 17 (1999), 881–888.
77. [77] Dolcetti, L., Peranzoni, E., Ugel, S., Marigo, I., Fernandez Gomez, A., Mesa, C., Geilich, M., Winkels, G., Traggiai, E., Casati, A., Grassi, F., Bronte, V., Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40 (2010), 22–35.
78. [78] Morales, J.K., Kmieciak, M., Knutson, K.L., Bear, H.D., Manjili, M.H., GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b−Gr1− bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res. Treat. 123 (2010), 39–49.
79. [79] Serafini, P., Carbley, R., Noonan, K.A., Tan, G., Bronte, V., Borrello, I., High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64 (2004), 6337–6343.
80. [80] Shojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y.G., Ferrara, N., G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 6742–6747.
81. [81] Bunt, S.K., Sinha, P., Clements, V.K., Leips, J., Ostrand-Rosenberg, S., Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176 (2006), 284–290.
82. [82] Bunt, S.K., Yang, L., Sinha, P., Clements, V.K., Leips, J., Ostrand-Rosenberg, S., Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67 (2007), 10019–10026.
83. [83] Sinha, P., Clements, V.K., Fulton, A.M., Ostrand-Rosenberg, S., Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67 (2007), 4507–4513.
84. [84] Rodriguez, P.C., Hernandez, C.P., Quiceno, D., Dubinett, S.M., Zabaleta, J., Ochoa, J.B., Gilbert, J., Ochoa, A.C., Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202 (2005), 931–939.
85. [85] Obermajer, N., Muthuswamy, R., Lesnock, J., Edwards, R.P., Kalinski, P., Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118 (2011), 5498–5505.
86. [86] Mao, Y., Sarhan, D., Steven, A., Seliger, B., Kiessling, R., Lundqvist, A., Inhibition of tumor-derived prostaglandin-E2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin. Cancer Res. 20 (2014), 4096–4106.
87. [87] Harris, R.E., Beebe-Donk, J., Alshafie, G.A., Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer, 6, 2006, 27.
88. [88] Meyer, C., Sevko, A., Ramacher, M., Bazhin, A.V., Falk, C.S., Osen, W., Borrello, I., Kato, M., Schadendorf, D., Baniyash, M., Umansky, V., Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 17111–17116.
89. [89] Talmadge, J.E., Hood, K.C., Zobel, L.C., Shafer, L.R., Coles, M., Toth, B., Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int. Immunopharmacol. 7 (2007), 140–151.
90. [90] Veltman, J.D., Lambers, M.E., van Nimwegen, M., Hendriks, R.W., Hoogsteden, H.C., Aerts, J.G., Hegmans, J.P., COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer, 10, 2010, 464.
91. [91] Eruslanov, E., Daurkin, I., Ortiz, J., Vieweg, J., Kusmartsev, S., Pivotal advance: tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE catabolism in myeloid cells. J. Leukoc. Biol. 88 (2010), 839–848.
92. [92] Cheng, P., Corzo, C.A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M.M., Ortiz, M., Nacken, W., Sorg, C., Vogl, T., Roth, J., Gabrilovich, D.I., Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205 (2008), 2235–2249.
93. [93] Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., Schadendorf, D., Utikal, J., Umansky, V., Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin. Cancer Res., 2015 Epub ahead of print.
94. [94] Sawanobori, Y., Ueha, S., Kurachi, M., Shimaoka, T., Talmadge, J.E., Abe, J., Shono, Y., Kitabatake, M., Kakimi, K., Mukaida, N., Matsushima, K., Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 111 (2008), 5457–5466.
95. [95] K. Parker, S. Ostrand-Rosenberg, High mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy, 2015, Submitted for publication.
96. [96] Liu, Y., Lai, L., Chen, Q., Song, Y., Xu, S., Ma, F., Wang, X., Wang, J., Yu, H., Cao, X., Wang, Q., MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J. Immunol. 188 (2012), 5500–5510.
97. [97] D. Beury, K.A. Carter, C. Nelson, M. Nyandjo, P. Fitzgerald, P. Sinha, A. Majeed, N. Wali, S. Ostrand-Rosenberg, Myeloid-derived suppressor cell survival and function are regulated by the transcription factor Nrf2, 2015, Submitted for publication.
98. [98] Chornoguz, O., Grmai, L., Sinha, P., Artemenko, K.A., Zubarev, R.A., Ostrand-Rosenberg, S., Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Mol. Cell. Proteomics: MCP, 10, 2011 M110.002980.
99. [99] Sinha, P., Chornoguz, O., Clements, V.K., Artemenko, K.A., Zubarev, R.A., Ostrand-Rosenberg, S., Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood 117 (2011), 5381–5390.
100. [100] Parker, K.H., Beury, D.W., Ostrand-Rosenberg, S., Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv. Cancer Res. 128 (2015), 95–139.
101. [101] Filipazzi, P., Huber, V., Rivoltini, L., Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol. Immunother. 61 (2012), 255–263.
102. [102] Montero, A.J., Diaz-Montero, C.M., Kyriakopoulos, C.E., Bronte, V., Mandruzzato, S., Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J. Immunother. 35 (2012), 107–115.
103. [103] Ioannou, M., Alissafi, T., Lazaridis, I., Deraos, G., Matsoukas, J., Gravanis, A., Mastorodemos, V., Plaitakis, A., Sharpe, A., Boumpas, D., Verginis, P., Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J. Immunol. 188 (2012), 1136–1146.
104. [104] Chou, H.S., Hsieh, C.C., Charles, R., Wang, L., Wagner, T., Fung, J.J., Qian, S., Lu, L.L., Myeloid-derived suppressor cells protect islet transplants by B7-H1 mediated enhancement of T regulatory cells. Transplantation 93 (2012), 272–282.
105. [105] Fujii, W., Ashihara, E., Hirai, H., Nagahara, H., Kajitani, N., Fujioka, K., Murakami, K., Seno, T., Yamamoto, A., Ishino, H., Kohno, M., Maekawa, T., Kawahito, Y., Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis. J. Immunol. 191 (2013), 1073–1081.
106. [106] Guan, Q., Moreno, S., Qing, G., Weiss, C.R., Lu, L., Bernstein, C.N., Warrington, R.J., Ma, Y., Peng, Z., The role and potential therapeutic application of myeloid-derived suppressor cells in TNBS-induced colitis. J. Leukoc. Biol. 94 (2013), 803–811.
107. [107] Li, Y., Tu, Z., Qian, S., Fung, J.J., Markowitz, S.D., Kusner, L.L., Kaminski, H.J., Lu, L., Lin, F., Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis. J. Immunol. 193 (2014), 2127–2134.
108. [108] Highfill, S.L., Rodriguez, P.C., Zhou, Q., Goetz, C.A., Koehn, B.H., Veenstra, R., Taylor, P.A., Panoskaltsis-Mortari, A., Serody, J.S., Munn, D.H., Tolar, J., Ochoa, A.C., Blazar, B.R., Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 116 (2010), 5738–5747.
109. [109] Yin, B., Ma, G., Yen, C.Y., Zhou, Z., Wang, G.X., Divino, C.M., Casares, S., Chen, S.H., Yang, W.C., Pan, P.Y., Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J. Immunol. 185 (2010), 5828–5834.
110. [110] Shi, M., Shi, G., Tang, J., Kong, D., Bao, Y., Xiao, B., Zuo, C., Wang, T., Wang, Q., Shen, Y., Wang, H., Funk, C.D., Zhou, J., Yu, Y., Myeloid-derived suppressor cell function is diminished in aspirin-triggered allergic airway hyperresponsiveness in mice. J. Allergy Clin. Immunol., 134, 2014 1163–1174.e1116.
111. [111] Kostlin, N., Kugel, H., Spring, B., Leiber, A., Marme, A., Henes, M., Rieber, N., Hartl, D., Poets, C.F., Gille, C., Granulocytic myeloid derived suppressor cells expand in human pregnancy and modulate T-cell responses. Eur. J. Immunol., 2014.
112. [112] Nair, R.R., Sinha, P., Khanna, A., Singh, K., Reduced myeloid-derived suppressor cells in the blood and endometrium is associated with early miscarriage. Am. J. Reprod. Immunol. 73 (2015), 479–486.
113. [113] Elahi, S., Ertelt, J.M., Kinder, J.M., Jiang, T.T., Zhang, X., Xin, L., Chaturvedi, V., Strong, B.S., Qualls, J.E., Steinbrecher, K.A., Kalfa, T.A., Shaaban, A.F., Way, S.S., Immunosuppressive CD71+ erythroid cells compromise neonatal host defence against infection. Nature 504 (2013), 158–162.